Peptide Schedule
Cardiogen4 residuesAEDREach bubble = one amino acid. Size = residue mass. Color = chemical class.Cardiogen Dosage Calculator
Cardiogen is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR), developed at the St.
10mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
Cycle Planner
Cardiogen Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~15-30 minutes (estimated, short-chain tetrapeptide)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Cardiogen Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Cardiogen (Ala-Glu-Asp-Arg) is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It's typically sold as oral capsules containing 20 mg of the active peptide complex. Standard protocols involve 10-20 day oral courses repeated every 3-6 months.
About Cardiogen
Cardiogen is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR), developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of Professor Vladimir Khavinson's program of tissue-specific short peptide regulators. It belongs to the "cytogen" class of bioregulators — synthesized short-chain peptides designed to target specific organ systems, in this case cardiac and cardiovascular tissue. Unlike larger peptide therapeutics that bind cell-surface receptors, Khavinson bioregulators are proposed to penetrate cell membranes and interact directly with DNA at specific promoter regions, modulating gene expression in a tissue-specific manner. In preclinical studies using organotypic tissue cultures from both young and old rats, cardiogen at picomolar concentrations stimulated cardiomyocyte proliferation — an effect that wasn't reproduced by any of the 20 individual L-amino acids tested at the same concentration. This suggests the intact tetrapeptide sequence is required for bioactivity. Immunohistochemical analysis showed cardiogen reduced p53 protein expression in myocardial tissue, indicating suppression of apoptotic pathways. Published evidence is limited to in vitro experiments and animal models, primarily from a single research group. No randomized controlled trials in humans have been published in Western peer-reviewed journals.